In phase 1 and phase 1b clinical trials, healthy human volunteers and PD patients treated with the LRRK2 inhibitor DNL201 had reduced urinary di-22:6-BMP concentrations [158]. This evidence concerns the gene LRRK2 and Parkinson disease.